|
KMID : 0391319930030010099
|
|
Korean Journal of Biological Response Modifiers
1993 Volume.3 No. 1 p.99 ~ p.106
|
|
|
Effect of Granulocyte Colony-Stimulating Factor (G-CSF) in Patients with Acute myelogenous Leukemia Receiving Intensive Induction Chemotherapy with Idarubicin and Ara-C
|
|
이종욱
김동욱/김병국/김춘추/민우성/박재후/박종원/박희숙/손창학
|
|
|
Abstract
|
|
|
Granulocyte colony-stimulating factor (G-CSF) induces the proliferation and differentiation of normal bone marrow granulocytic precursors and it has been used clinically to accelerate the recovery of normal hematopoiesis after chemotherapy or
bone
marrow transplantation.
We conducted a prospective, randomized, controlled study to determine the safety and efficacy of recombinant human G-CSF (rhG-CSF) after intensive induction chemotherapy with idarubicin and Ara-C in 44 patients with acute myelogenous leukemia
(AML).
Treatment with G-CSF (200㎍/㎡/day, subcutaneously or continuous infusion) was begun two days after the end of the induction chemotherapy and continued for 14 days.
Recovery of the neutrophil count to more than 500 or 1,000/㎣ was significanlty faster in the group treated with G-CSF than in the control group (p<0.01), but treatment with G-CSF had no effect on platelet recovery. Although the incidence of
febrile
episodes was almost the same, the duration of febrile days was significantly shorter in the group treated with G-CSF (p<0.01). Complete remission (CR) rate in both G-CSF group and control group was 77% (23/30) and 71% (10/14), respectively. The
toxicity
of G-CSF was minimal, and there was no evidence that G-CSF accelerated the regrowth of leukemic cells.
Our results suggest that rhG-CSF hastens neutrophil recovery and shortens the duration of febrile days after induction chemotherapy in patients with AML without significant toxicity. However, further observations are needed to assess whether the
use of
such a factor can affect the leukemia relapse.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|